Rhythm Pharmaceuticals
RYTM
101 hedge funds and large institutions have $1.45B invested in Rhythm Pharmaceuticals in 2022 Q3 according to their latest regulatory filings, with 35 funds opening new positions, 36 increasing their positions, 19 reducing their positions, and 22 closing their positions.
658% more capital invested
Capital invested by funds: $191M → $1.45B (+$1.25B)
500% more funds holding in top 10
Funds holding in top 10: 1 → 6 (+5)
149% more call options, than puts
Call options by funds: $36.2M | Put options by funds: $14.5M
89% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 19
59% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 22
15.58% more ownership
Funds ownership: 91.19% → 106.77% (+16%)
12% more funds holding
Funds holding: 90 → 101 (+11)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$53.5M |
| 2 |
BlackRock
New York
|
+$43.9M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
+$36M |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$35.5M |
| 5 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
+$35.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
|
-$9.65M |
| 2 |
Franklin Resources
San Mateo,
California
|
-$7.38M |
| 3 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$4.08M |
| 4 |
MAM
MPM Asset Management
Boston,
Massachusetts
|
-$3.77M |
| 5 |
Morgan Stanley
New York
|
-$3.73M |
RYTM Hedge Fund Activity: Q3 2022 in Review
101 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Rhythm Pharmaceuticals (RYTM) for Q3 2022, worth a combined $1.45B — up 658% from $191M a quarter earlier.
Buyers outnumbered sellers: 35 funds opened new RYTM positions and 22 closed out — a net gain of 13 holders — while 36 added to existing stakes and 19 trimmed.
The largest buyer was State Street, adding an estimated $53.5M. The largest seller was Janus Henderson Group, cutting an estimated $9.65M.
- 101 institutional investors held Rhythm Pharmaceuticals (RYTM) as of Q3 2022, up from 90 in Q2 2022.
- Funds reported $1.45B of Rhythm Pharmaceuticals stock for Q3 2022, up 658% quarter-over-quarter.
- 35 funds opened new Rhythm Pharmaceuticals positions in Q3 2022 and 22 closed out, a net change of +13 holders.
- The largest Rhythm Pharmaceuticals buyer in Q3 2022 was State Street, an estimated $53.5M added.
- The largest Rhythm Pharmaceuticals seller in Q3 2022 was Janus Henderson Group, an estimated $9.65M sold.
Based on aggregated 13F filings for Q3 2022.